Semaglutide Found To Have Shocking Benefit For Liver Disease Patients In New Study

Using semaglutide injections, scientists were capable to reverse life-threatening cases of liver illness successful a caller objective proceedings published successful The New England Journal of Medicine.

Semaglutide, which is traditionally a curen for type 2 diabetes, was fixed to participants who had been diagnosed pinch a life-threatening shape of liver illness called metabolic dysfunction associated steatohepatitis (MASH).

"This is simply a awesome measurement guardant successful nan field," said Arun Sanyal, M.D., head of nan VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, successful a video from VCU. "It provides patients pinch further choices erstwhile we deliberation astir treating fatty liver disease."

JOE ROGAN GAVE UP DRINKING ALCOHOL FOR THIS ONE SIMPLE REASON

MASH is simply a terrible shape of metabolic dysfunction-associated steatotic liver illness (MASLD), which was antecedently known arsenic non-alcoholic fatty liver disease, according to WebMD.

MASH is simply a terrible shape of metabolic dysfunction-associated steatotic liver illness (MASLD), which was antecedently known arsenic non-alcoholic fatty liver disease. (iStock)

Both MASH and MASLD are marked by excessive fat successful nan liver, which tin beryllium dangerous.

"Over time, nan buildup of fat successful nan liver tin lead to inflammation, liver fibrosis, cirrhosis and liver cancer," stated a property merchandise astir nan study.

FIRST GLP-1 PILL FOR WEIGHT LOSS, DIABETES SHOWS SUCCESS IN LATE-PHASE TRIAL

Researchers chose to analyse semaglutide arsenic a imaginable curen because this people of supplier has antecedently been shown to trim fat and liver scarring for group pinch MASH.

Between 2021 and 2023, 800 randomly selected participants crossed 37 countries received once-weekly injections of either semaglutide aliases a placebo, nan property merchandise stated. More than half had type 2 diabetes and astir 75% were obese.

Participants treated pinch semaglutide had improvements successful liver enzymes and different humor measures of liver fibrosis, on pinch 10.5% weight loss.  (iStock)

After 72 weeks of treatment, 62.9% of participants had little inflammation and fat accumulation successful their livers.

In nan placebo group, only 34.3% of participants knowledgeable a alteration successful symptoms.

"The liver really starts looking substantially amended nether nan microscope successful these patients," noted Sanyal.

OZEMPIC, OTHER SEMAGLUTIDES LINKED TO HAIR LOSS: HERE'S WHAT TO KNOW

The researchers besides recovered that 36.8% of nan semaglutide group saw improvements successful their liver fibrosis, versus 22.4% successful nan placebo group.

Participants treated pinch semaglutide besides saw improvements successful liver enzymes and humor measures of liver fibrosis, arsenic good arsenic 10.5% weight loss. 

"I've been moving pinch GLP-1 treatments for 16 years and these results are hugely exciting."

Some adverse experiences were much communal successful nan semaglutide group, including nausea, diarrhea, constipation and vomiting.

"Novo Nordisk continues to research semaglutide crossed metabolic and cardiovascular health, including MASH, a information pinch constricted curen options for patients and healthcare professionals," said Anna Windle, PhD, elder vice president of objective development, aesculapian and regulatory affairs astatine Novo Nordisk, shaper of Ozempic and Wegovy, successful a property merchandise provided to Fox News Digital.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"We are encouraged by these published findings successful nan NEJM and what this could mean for patients. Based connected these data, we look guardant to moving pinch regulatory authorities to bring this imaginable caller curen action to patients."

"While these results must beryllium treated pinch caution, nan study shows semaglutide tin beryllium an effective instrumentality to dainty this precocious liver disease," said nan leader of nan trial. (iStock)

"While these results must beryllium treated pinch caution, nan study shows semaglutide tin beryllium an effective instrumentality to dainty this precocious liver disease," said lead interrogator Professor Philip Newsome, head of nan Roger Williams Institute of Liver Studies astatine King's College London, successful nan release.

CLICK HERE TO GET THE FOX NEWS APP

"I've been moving pinch GLP-1 treatments for 16 years and these results are hugely exciting," he added.

Sanyal noted that semaglutide had antecedently been shown to beryllium beneficial for obesity, glucosuria and bosom disease.

"Now we tin adhd liver illness to that list."

For much Health articles, visit www.foxnews.com/health

Looking ahead, nan investigation squad plans to gather data from astir 1,200 participants successful 37 countries for up to 5 years to find semaglutide's effect connected semipermanent liver complications.